Cidel Asset Management Inc. Has $42.02 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Cidel Asset Management Inc. raised its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 8.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 571,705 shares of the company's stock after acquiring an additional 46,033 shares during the quarter. AstraZeneca makes up about 2.7% of Cidel Asset Management Inc.'s investment portfolio, making the stock its 7th largest holding. Cidel Asset Management Inc.'s holdings in AstraZeneca were worth $42,020,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in shares of AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company's stock worth $379,000 after acquiring an additional 2,789 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of AstraZeneca by 1.4% in the fourth quarter. Rhumbline Advisers now owns 29,123 shares of the company's stock valued at $1,908,000 after purchasing an additional 404 shares during the last quarter. Oppenheimer & Co. Inc. increased its holdings in shares of AstraZeneca by 6.0% in the fourth quarter. Oppenheimer & Co. Inc. now owns 23,925 shares of the company's stock valued at $1,568,000 after purchasing an additional 1,361 shares during the last quarter. SVB Wealth LLC bought a new position in shares of AstraZeneca in the fourth quarter valued at about $784,000. Finally, US Bancorp DE lifted its stake in shares of AstraZeneca by 2.9% during the 4th quarter. US Bancorp DE now owns 239,233 shares of the company's stock worth $15,675,000 after buying an additional 6,814 shares during the last quarter. Institutional investors own 20.35% of the company's stock.

AstraZeneca Stock Performance

NASDAQ AZN traded down $1.53 on Friday, reaching $69.60. The stock had a trading volume of 6,768,010 shares, compared to its average volume of 5,252,689. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. The company has a market cap of $215.85 billion, a P/E ratio of 27.95, a price-to-earnings-growth ratio of 1.28 and a beta of 0.37. The firm has a fifty day moving average of $70.78 and a two-hundred day moving average of $70.60. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same period in the prior year, the company posted $2.06 earnings per share. AstraZeneca's revenue was up 7.2% compared to the same quarter last year. On average, equities research analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas assumed coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, AstraZeneca has a consensus rating of "Moderate Buy" and an average price target of $85.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.